c-Myc as a therapeutic target in cancer.
Identifieur interne : 004308 ( Main/Curation ); précédent : 004307; suivant : 004309c-Myc as a therapeutic target in cancer.
Auteurs : Edward V. Prochownik [États-Unis]Source :
- Expert review of anticancer therapy [ 1473-7140 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Humains (MeSH), Oligodésoxyribonucléotides antisens (usage thérapeutique), Protéines proto-oncogènes c-myc (antagonistes et inhibiteurs), Protéines proto-oncogènes c-myc (génétique), Protéines proto-oncogènes c-myc (métabolisme), Systèmes de délivrance de médicaments (méthodes), Tumeurs (génétique), Tumeurs (traitement médicamenteux).
- MESH :
- antagonistes et inhibiteurs : Protéines proto-oncogènes c-myc.
- génétique : Protéines proto-oncogènes c-myc, Tumeurs.
- métabolisme : Protéines proto-oncogènes c-myc.
- méthodes : Systèmes de délivrance de médicaments.
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Oligodésoxyribonucléotides antisens.
- Animaux, Humains.
English descriptors
- KwdEn :
- Animals (MeSH), Drug Delivery Systems (methods), Humans (MeSH), Neoplasms (drug therapy), Neoplasms (genetics), Oligodeoxyribonucleotides, Antisense (therapeutic use), Proto-Oncogene Proteins c-myc (antagonists & inhibitors), Proto-Oncogene Proteins c-myc (genetics), Proto-Oncogene Proteins c-myc (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Proto-Oncogene Proteins c-myc.
- chemical , genetics : Proto-Oncogene Proteins c-myc.
- chemical , metabolism : Proto-Oncogene Proteins c-myc.
- chemical , therapeutic use : Oligodeoxyribonucleotides, Antisense.
- drug therapy : Neoplasms.
- genetics : Neoplasms.
- methods : Drug Delivery Systems.
- Animals, Humans.
Abstract
c-Myc is frequently deregulated in human cancers. The c-Myc oncoprotein is a transcription factor, with many of its target genes encoding proteins that initiate and maintain the transformed state. c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. This knowledge highlights several points that might be amenable to attack. This review summarizes progress in controlling the extent of c-Myc transcription, translation, interaction with other myc network members, DNA binding and transcriptional activation. Inhibition of c-Myc can be achieved with many of these approaches; however, clinical efficacy will likely require intervention at several levels, perhaps in combination with traditional chemotherapeutic drugs or agents that target other oncoproteins.
DOI: 10.1586/14737140.4.2.289
PubMed: 15056059
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004308
Links to Exploration step
pubmed:15056059Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">c-Myc as a therapeutic target in cancer.</title><author><name sortKey="Prochownik, Edward V" sort="Prochownik, Edward V" uniqKey="Prochownik E" first="Edward V" last="Prochownik">Edward V. Prochownik</name><affiliation wicri:level="1"><nlm:affiliation>Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Rangos Research Center, Room 2100, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. edward_prochownik@poplar.chp.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Rangos Research Center, Room 2100, 3460 Fifth Avenue, Pittsburgh, PA 15213</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15056059</idno><idno type="pmid">15056059</idno><idno type="doi">10.1586/14737140.4.2.289</idno><idno type="wicri:Area/Main/Corpus">004308</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">004308</idno><idno type="wicri:Area/Main/Curation">004308</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">004308</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">c-Myc as a therapeutic target in cancer.</title><author><name sortKey="Prochownik, Edward V" sort="Prochownik, Edward V" uniqKey="Prochownik E" first="Edward V" last="Prochownik">Edward V. Prochownik</name><affiliation wicri:level="1"><nlm:affiliation>Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Rangos Research Center, Room 2100, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. edward_prochownik@poplar.chp.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Rangos Research Center, Room 2100, 3460 Fifth Avenue, Pittsburgh, PA 15213</wicri:regionArea></affiliation></author></analytic><series><title level="j">Expert review of anticancer therapy</title><idno type="ISSN">1473-7140</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Drug Delivery Systems (methods)</term><term>Humans (MeSH)</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (genetics)</term><term>Oligodeoxyribonucleotides, Antisense (therapeutic use)</term><term>Proto-Oncogene Proteins c-myc (antagonists & inhibitors)</term><term>Proto-Oncogene Proteins c-myc (genetics)</term><term>Proto-Oncogene Proteins c-myc (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Humains (MeSH)</term><term>Oligodésoxyribonucléotides antisens (usage thérapeutique)</term><term>Protéines proto-oncogènes c-myc (antagonistes et inhibiteurs)</term><term>Protéines proto-oncogènes c-myc (génétique)</term><term>Protéines proto-oncogènes c-myc (métabolisme)</term><term>Systèmes de délivrance de médicaments (méthodes)</term><term>Tumeurs (génétique)</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Proto-Oncogene Proteins c-myc</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Proto-Oncogene Proteins c-myc</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Proto-Oncogene Proteins c-myc</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Oligodeoxyribonucleotides, Antisense</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines proto-oncogènes c-myc</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines proto-oncogènes c-myc</term><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines proto-oncogènes c-myc</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Systèmes de délivrance de médicaments</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Oligodésoxyribonucléotides antisens</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">c-Myc is frequently deregulated in human cancers. The c-Myc oncoprotein is a transcription factor, with many of its target genes encoding proteins that initiate and maintain the transformed state. c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. This knowledge highlights several points that might be amenable to attack. This review summarizes progress in controlling the extent of c-Myc transcription, translation, interaction with other myc network members, DNA binding and transcriptional activation. Inhibition of c-Myc can be achieved with many of these approaches; however, clinical efficacy will likely require intervention at several levels, perhaps in combination with traditional chemotherapeutic drugs or agents that target other oncoproteins.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15056059</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1473-7140</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert review of anticancer therapy</Title><ISOAbbreviation>Expert Rev Anticancer Ther</ISOAbbreviation></Journal><ArticleTitle>c-Myc as a therapeutic target in cancer.</ArticleTitle><Pagination><MedlinePgn>289-302</MedlinePgn></Pagination><Abstract><AbstractText>c-Myc is frequently deregulated in human cancers. The c-Myc oncoprotein is a transcription factor, with many of its target genes encoding proteins that initiate and maintain the transformed state. c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. This knowledge highlights several points that might be amenable to attack. This review summarizes progress in controlling the extent of c-Myc transcription, translation, interaction with other myc network members, DNA binding and transcriptional activation. Inhibition of c-Myc can be achieved with many of these approaches; however, clinical efficacy will likely require intervention at several levels, perhaps in combination with traditional chemotherapeutic drugs or agents that target other oncoproteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prochownik</LastName><ForeName>Edward V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Rangos Research Center, Room 2100, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. edward_prochownik@poplar.chp.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA78259</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL33641</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Anticancer Ther</MedlineTA><NlmUniqueID>101123358</NlmUniqueID><ISSNLinking>1473-7140</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020319">Oligodeoxyribonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020319" MajorTopicYN="N">Oligodeoxyribonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016271" MajorTopicYN="N">Proto-Oncogene Proteins c-myc</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>155</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15056059</ArticleId><ArticleId IdType="pii">ERA040214</ArticleId><ArticleId IdType="doi">10.1586/14737140.4.2.289</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:15056059
|texte= c-Myc as a therapeutic target in cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:15056059" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |